Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients

Inclusion Criteria: * Patients with histologically- or cytologically- documented NSCLC who present unresectable stage IIIA-IIIB-IIIC disease, according to 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology). * ECOG 0-1. * PDL1\>1%. * Age ≥ 18 years at time of study * Patients without progression after cCRT, that are going to receive IO treatment (Durvalumab) for 12 months as subsequent treatment as per standard clinical practice * Patient capable of proper therapeutic compliance and accessible for correct follow-up. * Patients must have signed, dated and IRB/EC-approved written informed consent form in accordance with regulatory and institutional guidelines. Exclusion Criteria: * Patients who refuse to sign and date an IRB/IEC-approved written informed consent form. * No possibility of venipuncture * Any medical, mental, or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information.